MSC Medium for Drug Discovery — Reproducible Screening Models

MSCs are used across drug discovery as stromal components in co-culture models, as primary responders in inflammation assays and as building blocks for 3D disease models (fibrosis, osteoarthritis, metabolic disease). In all of these, the functional state of the MSC population directly determines assay sensitivity and Z-factor.

Serum-lot switching — even within the same supplier — shifts MSC proliferation rate, differentiation bias and cytokine secretion profile. CROs running multi-month screening campaigns see this as unexplained drift between assay batches.

CelliMax MSC1 removes serum from the expansion equation. Same formulation, same certified specifications, same MSC functional state — batch after batch.

Screening applications

• Fibrosis models: MSC-fibroblast co-culture with defined MSC starting material — consistent stromal activation baseline for anti-fibrotic compound screening
• Osteoarthritis / cartilage: chondrogenically primed MSCs from defined expansion as assay input — reproducible ECM deposition endpoints
• Inflammation / NF-kB reporter assays: MSC immunomodulation function preserved across passages in MSC1 — stable assay window for anti-inflammatory compound panels
• Metabolic disease models: adipogenic differentiation capacity maintained — predictable lipid accumulation endpoints for NASH / obesity screening

For CROs: supply continuity and documentation

CelliMax MSC1 is available in large-format powder batches (250 kg GMP grade) and pre-filled liquid (200 L per run). For CROs running continuous screening campaigns, the powder format enables in-house reconstitution at fixed schedule — no dependence on serum lot qualification cycles. Full material documentation supplied per batch.